Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases
- 25 November 2010
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 7 (6), 719-734
- https://doi.org/10.1177/1740774510386390
Abstract
Background There has been tremendous progress over the last decade in the development of health products — drugs, vaccines, and diagnostics — for neglected diseases. There are now dozens of candidate products in the pipeline.Keywords
This publication has 29 references indexed in Scilit:
- The Unintended Consequences of Clinical Trials RegulationsPLoS Medicine, 2009
- Turning Neglected Tropical Diseases Into Forgotten MaladiesHealth Affairs, 2009
- A Business Plan To Help The ‘Global South’ In Its Fight Against Neglected DiseasesHealth Affairs, 2009
- A New Vaccine for Tuberculosis: The Challenges of Development and DeploymentJournal of Bioethical Inquiry, 2009
- Ethical and Scientific Implications of the Globalization of Clinical ResearchNew England Journal of Medicine, 2009
- Do we need to adjudicate major clinical events?Clinical Trials, 2008
- Sensible guidelines for the conduct of large randomized trialsClinical Trials, 2008
- The impact of privacy and confidentiality laws on the conduct of clinical trialsClinical Trials, 2008
- Randomized Trials in Vulnerable PopulationsClinical Trials, 2008
- The European Agency for the Evaluation of Medicinal Products’ Centralized Procedure for Product Approval: Current StatusDrug Information Journal, 1999